CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) approved clinical trials for Leuprorelin Extended-release Injection (SYH9016), according to a Friday filing with the Hong Kong bourse.
The medication, meant to treat solid tumors, does not require complicated preparation before administration. Its thinner injection needle delivers a smaller dosing volume, which is expected to reduce pain at the injection site compared with its predecessor, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.